The Siesta Group

Press & News

February 24, 2010: The Siesta Group expands its research activities and clinical trials business

Vienna, Austria – The Siesta Group, creator of the Somnolyzer 24x7 automated scoring technology, has sold its autoscoring business to Royal Philips Electronic and will focus its activities on sleep-related research and its clinical trial business.

“The successful development, market launch and now sale of the Somnolyzer 24x7 to Philips is a significant milestone for our company. The transaction allows a fast and global penetration of the field with the most advanced and clinically validated autoscoring technology. It also gives The Siesta Group the resources to expand its research in sleep measurement and grow its proven clinical trials business.

With an increasing demand for development services in CNS- and sleep-related drugs and the reputation that TSG earned as a leading-edge sleep technology company, we expect significant growth in our drug and device development service business,“ said Georg Dorffner, CEO of The Siesta Group. “Aside of that, we are developing and validating new concepts for the measurement of sleep and vigilance that aim to become tomorrow’s gold standard.”

The reliable and valid measurement of sleep and, more generally, cortical activity through EEG, is increasingly becoming a central concern in the development of CNS-active drugs, reaching much farther than drugs targeting sleep disorders alone. The market is in need for more efficient high quality solutions to deriving major sleep and EEG biomarkers, a need that is perfectly addressed by The Siesta Group’s technology.

While Somnolyzer 24x7 is now property of Philips Respironics being exploited in the diagnostic sleep center business, The Siesta Group remains the sole company making available this technology to the benefit of clinical trials worldwide.

 

<< Back to overview

You are here: Home | NEWS & EVENTS | Press & News | February 24, 2010: The Siesta Group expands its research activities and clinical trials business